Green Molecular, a spin-out of the University of Valencia, licences its pharma tech to cosmetics firm ChromaDex.
US-based ChromaDex has announced a licensing agreement with biotech Green Molecular, a spin-out of Spain’s University of Valencia.
The natural products firm is building a portfolio of patents relating to pterostilbene, a product used in skincare and developed by Green Molecular. It is the eighth patent ChromaDex has acquired for pterostilbene, and the second for the related product pTeroPure, having signed a similar deal with the University of California, Irvine in 2011.
Frank Jaksch, chief executive of ChromaDex, said: “We intend to continue our strategy to build intellectual property around our ingredients. By building a robust skincare IP portfolio, we are positioning to become a meaningful provider of patent protected innovative ingredient technologies to this growing multi-billion dollar market place.”
Dr. Jose M. Estrela, research director of Green Molecular, added: “I am excited to have this collaboration with ChromaDex. Pterostilbene, as well as its possible association with other structurally-related natural polyphenols, has multiple applications in Biomedicine. Working with ChromaDex will allow for pterostilbene’s cosmetic and pharmaceutical applications in skin care and pathology to reach the market.”
